Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes

Berkeley, CA – December 19, 2018

Carmot Therapeutics announced today the initiation of a clinical trial for the treatment of type 2 diabetes with CT-868, a dual modulator of the GLP-1 and GIP incretin receptors. The Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of CT-868 in overweight or obese but otherwise healthy volunteers and patients with type 2 diabetes.

“The therapeutic benefits of simultaneously targeting multiple incretin receptors is of great interest, but balancing efficacy and tolerability has been a challenge,” commented Stig K. Hansen, PhD, Carmot’s Chief Executive Officer. “CT-868 is a dual incretin modulator with unique pharmacology and has demonstrated excellent efficacy and tolerability in pre-clinical models. The Phase 1 study is designed to closely track safety and adverse effects with pharmacodynamic readouts. We believe CT-868 could provide better outcomes with fewer side effects for patients with type 2 diabetes and obesity.”

The Phase 1 study is a randomized, double-blind, placebo-controlled, dose escalation trial in overweight or obese healthy volunteers and patients with type 2 diabetes. The first phase of the study will evaluate CT-868 in single ascending doses. The second phase of the study will consist of multiple ascending doses over 14 days. The third phase will evaluate repeat dosing of CT-868 in patients with type 2 diabetes over a 28-day period and will include additional assessments of body weight and body fat composition.

About Carmot Therapeutics, Inc.
Carmot Therapeutics (“Carmot”) is a biotechnology company dedicated to the discovery and development of innovative medicines. Carmot applies a transformative and patented drug discovery approach, Chemotype Evolution, to overcome major limitations in existing discovery methods, providing Carmot a unique opportunity to tackle challenging disease targets and identify superior therapeutics. Carmot is applying Chemotype Evolution internally and in collaboration with industry partners such as Amgen and Genentech. Carmot has identified drug leads targeting class-B GPCRs, protein-protein interactions, and deubiquitinating enzymes and is advancing a portfolio of wholly-owned programs in metabolic disease and oncology.

Contact information:
James Watson, Chief Business Officer
bd@carmot.us
www.carmot.us